Wang Y.-H.JA-DER LIANGWANG-HUEI SHENGFENG-MING TIENChen, Chien-YuanChien-YuanChenHWEI-FANG TIEN2021-01-042021-01-0420190145-2126https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065013832&doi=10.1016%2fj.leukres.2019.05.001&partnerID=40&md5=42822f64f3fee2a6ea1f1519c7b0e1c7https://scholars.lib.ntu.edu.tw/handle/123456789/537374[SDGs]SDG3dasatinib; entecavir; hepatitis B antibody; hepatitis B core antibody; hepatitis B surface antigen; hepatitis B(e) antigen; imatinib; nilotinib; ponatinib; protein tyrosine kinase inhibitor; virus DNA; protein kinase inhibitor; adult; aged; antiviral therapy; chronic myeloid leukemia; cohort analysis; female; follow up; hepatitis B; Hepatitis B virus; human; incidence; Letter; major clinical study; male; middle aged; priority journal; retrospective study; serology; treatment outcome; virus carrier; virus reactivation; young adult; adolescent; chronic myeloid leukemia; drug effect; hepatitis B; pathology; prognosis; Taiwan; very elderly; virology; virus activation; Adolescent; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Virus Activation; Young Adultletter10.1016/j.leukres.2019.05.001310756692-s2.0-85065013832